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fully satisfactory, a high recurrence rate is observed and preven-
tion strategies are not available. HPV vaccination studies have
shown high efﬁcacy against HPV-induced lesions such as GW.
Before implementing a vaccination programme, data on the inci-
dence and prevalence of GW and their associated treatment costs
are crucial. The objective of this study was to estimate these data.
METHODS: 217 specialists (gynecologists, urologists and der-
matologists) were asked to record the number of patients, aged
14–64yrs, presenting with GW between February and April
2005. The average number of patients per specialist was used to
estimate the annual number of patients. Specialists also con-
ducted a chart review of 189 previously diagnosed GW patients
visiting them in the same period. Resource use, collected from
records going back to February 2004, included visits, diagnos-
tics, medications, procedures and adverse events. The cost of
treating patients with an existing GW diagnosis was calculated
using the average cost per patient and the extrapolated annual
number of existing patients. Indirect costs were included.
RESULTS: It was estimated that there are around 57,000 new
cases and 38,000 existing cases of GW annually in Germany.
Mean treatment duration was 6.7 months, with an average of
3.2 visits to a specialist. 95% of patients had a visual exam, and
the most used diagnostics included Pap smears (25.9%), biop-
sies (25.4%) and colposcopies (24.9%). Most common therapies
were imiquimod (34.4%), electrosurgery (26.5%), laser therapy
(19.1%) and cryotherapy (17.5%). The mean annual treatment
cost per existing patient was €950. The overall estimated treat-
ment costs were €36 million per year; of which €7 million indi-
rect costs. CONCLUSION: The management of GW presents a
high burden to society that could potentially be reduced using a
quadrivalent HPV vaccine.
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OBJECTIVE: New advances in health care have shifted concern
from infectious to chronic illnesses and therefore a new empha-
sis in the assessment of satisfaction with pharmacological treat-
ment has risen. A new generic questionnaire to measure
Satisfaction with medicines is under construction. Item reduction
and factorial validity are discussed here. METHODS: The initial
instrument was composed by 36 items, arranged in 6 dimensions:
1- Efﬁcacy and symptom relieve (5 items), 2- Ease and conve-
nience (6 items), 3- Impact on HRQoL (4 items), 4- Satisfaction
with Medical Care (4 items), 5- Medication Side Effects (8
items), and 6- Overall satisfaction (9 items). Items and dimen-
sions where extracted from review of previous English instru-
ments, a panel compose by 8 experts, and 4 focus groups with
chronic patients. A convenience sample of 156 patients was used,
representative of 7 prevalent chronic pathologies (Diabetes type
II, Hypertension, Osteoarthritis, Prostate problems,
EPOC/Asthma, Depression, and Migraine). Classic psychomet-
ric theory item analysis techniques, exploratory factor analysis,
and conﬁrmatory factor analysis (to estimate accurately factor
correlations) were applied. RESULTS: The questionnaire was
reduced to a new version of 5 dimensions assessed by 14 items,
plus a dimension of Satisfaction with Medication Side Effects (3
items) to be corrected separately due to an important ﬂoor effect.
The reduced version presents an overall Cronbach alpha of
0.881, acceptable goodness of ﬁt indexes, and all factor loadings
are signiﬁcant (p < 0.001). Dimensions are well formed and cor-
relate in different degrees, but the dimension of Satisfaction with
Medical Care shows a relevant relation only with Impact on
HRQoL (r = 0.45). CONCLUSION: The questionnaire shows
good reliability and validity properties. The 5 + 1 proposed
dimensions are stable and well deﬁned in a 17-item form. Results
support that the questionnaire can be used to compute an overall
meaningful score.
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The special interest group (SIG) on Translation and Cultural
Adaptation (TCA) had its ﬁrst meeting in Hong Kong at the
2004 Annual ISOQOL meeting. The overall objective of the
TCA SIG is to identify and advance research in different areas
of interest to all parties involved in the ﬁeld of Translation and
Cultural Adaptation. Three priority areas of research were iden-
tiﬁed and organised in three subgroups: translation difﬁculties,
equivalences and methodologies. OBJECTIVES: The objectives
of subgroup one are: 1. To collect, review and analyse examples
of translations difﬁculties in the adaptation of Patient-Reported
Outcomes (PRO) measures; 2. To create a list of “good prac-
tices” for developers of questionnaires and translators, based on
the review of common translation difﬁculties and proposed solu-
tions on how to prevent them. METHODS: The group has
organised its activities in 4 steps: 1. Categorisation of difﬁcul-
ties; 2. Collection of examples of translation difﬁculties; 3.
Review of examples; and 4. Recommendations. RESULTS:
Translation difﬁculties were divided into categories according to:
1. Their position within the PRO questionnaire (i.e. Demo-
graphics, levels of education, “race”, Instructions, Items and
Response Choices); 2.The layout used, e.g. e-layout, tables, font-
related problems; and 3. Their nature: Cultural (Is the construct
to be measured relevant in the target cultures?); Conceptual and
Semantic (Do the items represent the construct deﬁnition?); Syn-
tactic; and Idiomatic. Examples of translation difﬁculties for
each category deﬁned previously and for a selection of families
and branches of languages have been collected and will be pre-
sented. Recommendations on how to prevent potential transla-
tion difﬁculties will be proposed to developers of PRO
questionnaires. CONCLUSIONS: The translation of PRO mea-
sures is a difﬁcult task. “Good practices” for the development
and translation of PRO measures should be implemented to facil-
itate the use of linguistically valid PRO measures in international
research.
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OBJECTIVES: To analyse variation in clinical injury incidence
of 7 European countries, and to determine whether using differ-
ent injury indicators can minimize the bias in clinical injury 
incidence data and increase the comparability of the data.
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METHODS: Within the framework of an international project
(EUROCOST) Hospital Discharge Registers of 7 European
countries were analysed. To reduce heterogeneity, clinical inci-
dence was determined using different injury indicators, based on
a) health care use; b) anatomical criteria; or c) expected outcome.
The following existing and newly developed injury indicators
were tested: admissions excluding day cases (a), length of stay
4+ days and 7+ days (a), serious long-bone fractures (b), radio-
logical veriﬁable fractures (b), serious non-fatal injuries (c),
injuries with a moderate to high disability weight (Global Burden
of Disease weights and Dutch weights (IBIS)) (c). RESULTS:
Clinical injury incidence varied substantially in the rough data,
ranging from 6.6 to 22.9 per 1000 person years. Exclusion of
day cases and short-term admissions both led to an increased
variation in clinical incidence. The anatomical indicators
“serious long bone fractures” and “selected radiologically veri-
ﬁable fractures”, as well as both indicators based on disability
resulted in at least comparable variation in clinical incidence and
reduced variation in median length of stay in hospital as opposed
to the rough data. Contrary to rough data, those four indicators
showed reasonable (serious long bone fractures) to good associ-
ations with mortality rates. They were responsible for almost
equal parts of the hospital costs of injury (40–44%). CON-
CLUSIONS: Comparing only serious injuries with an objective
need for hospital admission based on disability weights (GBD
and IBIS) or on anatomical criteria (serious long bone fractures
and selected radiologically veriﬁable fractures) consistently
reduced the inﬂuence of registration and health care practices on
clinical incidence variation, which improved the comparability
of clinical injury incidence data.
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OBJECTIVES: To assess the contribution of prevention and
medical care to the improvement in population health, as part
of an overall assessment of the current cost-effectiveness of
health care. METHODS: We calculated the difference between
the current incidence, prevalence, and mortality of major health
problems, and those in a situation without prevention and
medical care (“partial null”). Major health problems include
among others infectious diseases, cancers and cardiovascular dis-
eases. The partial null was reconstructed with (if relevant his-
torical) data on disease-speciﬁc mortality, case fatality, incidence,
and knowledge of the natural history, combined with trend
analysis, and with relevant literature on e.g. the impact of antibi-
otics on infectious disease epidemiology. The separate impact of
prevention (predominantly screening, vaccination) and medical
care was disentangled by isolating the impact of changes in
(stage-speciﬁc) incidence on the one hand, and changes in case
fatality and stage-speciﬁc prevalence on the other hand. Histor-
ical changes in health behaviour (predominantly smoking) as a
possible result of public health interventions was included in a
subanalysis. Other behavioural changes, such as weight gain and
sexual behaviour, were regarded autonomous trends. All epi-
demiological data were age- and sex-speciﬁc. With multistate
lifetable modeling techniques the incidence, prevalence of disease
stages, disease-speciﬁc disability weights, and mortality were
combined to calculate disability adjusted life expectancy in the
current and null situation. RESULTS: Preliminary results will be
presented on infectious diseases and cancers. CONCLUSIONS:
Conclusions cannot yet be drawn. In a next step the results will
be combined with recent cost-of-illness data to calculate disease-
speciﬁc cost-effectiveness of prevention and medical care.
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Although standardisation of costing methodology is a prerequi-
site for the consistency and comparability of health economic
results it is often seen as insufﬁcient. There exist a number of
country-speciﬁc guidelines for the costing process in economic
evaluations, but they often stay vague, especially with regard 
to the empirically based valuation of resource consumption.
OBJECTIVE: To present a system of unit costs for the health
care system in Germany that reﬂects a societal perspective and
that ensures consistency and comparability of study results
between different intervention studies by following uniform val-
uation standards. METHODS: The valuation set is compatible
with the measurement of resource consumption derived from
patient reported data. Data sources for the valuation are registry
data, national statistics, charges and tariffs. The primary goal
was to approximate a national average by considering and
weighting different reimbursement schemes of private and public
health insurance. RESULTS: The valuation set includes all basic
direct and indirect cost components. As an example the valua-
tions for physician services are based on average reimbursement
per visit: A visit to the general practitioner is valued €15, costs
for visits to specialists range from €14 (psychiatrist) to €80 (radi-
ologist). Inpatient stays are valued by department-speciﬁc per
diem rates ranging form €260 (orthopaedics) to €481(neuro
surgery). Cost of a work day lost amount to €89 following a
human capital approach. The friction period when adopting the
friction cost approach is 72 days. CONCLUSIONS: The pro-
posed set of unit costs is based on average valuation of resource
consumption. As most cost components are not derived from
market prices but are based on administrative cost and/or remu-
neration data, institutional changes may have impact on the val-
uation of resource consumption. This should be considered when
empirical unit costs are updated.
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OBJECTIVES: To compare and evaluate freeware options for
bootstrap analyses of incremental cost effectiveness data.
METHODS: Obenchain’s ICEplane software can be down-
loaded and installed from www.math.iupui.edu/~indyasa/
bobdown.htm. This software was compared against the web-
based bootstrap analyses available online at HealthStrategy.com.
Three datasets, that are downloadable from the ICEplane site,
were used in this software comparison. The three datasets are
from published studies dealing with abciximab (ABX), pindolol
(PIN) and tricyclic antidepressants (TCA). RESULTS: ICEplane
must be installed on MS Windows operating systems, in contrast
to the Health Strategy program that runs online through any
operating system with browsers including Internet Explorer,
Netscape or Firefox. Both software options provide output
